Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline
Autolus Therapeutics Q3 Earnings Call Highlights
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
Autolus Therapeutics (NASDAQ:AUTL) Q3 2026 Revenue Beat Masks Wider Loss as AUCATZYL Launch Remains in Focus
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics Q3 2026 Earnings Call Transcript
Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M
Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven
Autolus Therapeutics: Key Questions For The Near Term
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.